A MICROSPHERE-BASED VACCINE PREVENTS AND REVERSES NEW-ONSET AUTOIMMUNE DIABETES

Brett Phillips¹, Karen Nylander¹, Jo Harnaha¹, Jennifer Machen¹, Robert Lakomy¹, Alexis Styche¹, Kimberly Gillis⁵, Larry Brown², Michael Gallo², Janet Knox², Kenneth Hogeland², Massimo Trucco¹, Nick Giannoukakis¹,³

¹Diabetes Institute, Division of Immunogenetics, Dept. Of Pediatrics, University of Pittsburgh School of Medicine, PA USA 15213
²Epic Therapeutics, a wholly-owned subsidiary of Baxter Healthcare Corporation, 220 Norwood Park South, Norwood, MA USA 02062
³Dept. of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA USA, 15213

Running Title: Diabetes-suppressive microspheres

Corresponding Author:
Nick Giannoukakis, Ph.D.
Dept. of Pathology
University of Pittsburgh School of Medicine
Diabetes Institute
Rangos Research Center
3460 Fifth Avenue
Pittsburgh, PA 15213
USA
ngiann1@pitt.edu

Received for publication 11 April 2007 and accepted in revised form 22 February 2008.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org.
ABSTRACT

Objective: This study was aimed at ascertaining the efficacy of antisense oligonucleotide-formulated microspheres to prevent type 1 diabetes and to reverse new-onset disease.

Research Design And Methods: Microspheres carrying antisense oligonucleotides to CD40, CD80 and CD86 were delivered into non-obese diabetic (NOD) mice. Glycemia was monitored to determine disease prevention and reversal. In recipients that remained and/or became diabetes-free, spleen and lymph node T-cells were enriched in order to determine the prevalence of Foxp3+ putative T regulatory cells. Splenocytes from diabetes-free microsphere-treated recipients were adoptively cotransferred with splenocytes from diabetic NOD mice into NOD-scid recipients. Live animal in vivo imaging measured the microsphere accumulation pattern. To rule out nonspecific systemic immunosuppression, splenocytes from successfully-treated recipients were pulsed with beta cell antigen, ovalbumin or cocultured with allogeneic splenocytes.

Results: The microspheres prevented type 1 diabetes and, most importantly, exhibited a capacity to reverse clinical hyperglycemia, suggesting reversal of new onset disease. The microspheres augmented Foxp3+ T regulatory cells, induced hyporesponsiveness to NOD-derived pancreatic beta cell antigen, without compromising global immune responses to alloantigens and nominal antigens. T-cells from successfully-treated mice suppressed adoptive transfer of disease by diabetogenic splenocytes into secondary immunodeficient recipients. Finally, microspheres accumulated within the pancreas and the spleen following either intraperitoneal or subcutaneous injection. Dendritic cells from spleen of the microsphere-treated mice exhibit decreased cell surface CD40, CD80 and CD86.

Conclusions: This novel microsphere formulation represents the first diabetes-suppressive and reversing nucleic acid vaccine which confers an immunoregulatory phenotype to endogenous dendritic cells.
Diabetes-suppressive microspheres

Type 1 diabetes mellitus is a disorder of glucose homeostasis caused by a chronic autoimmune inflammation of the pancreatic islets of Langerhans (1). The ultimate outcome is the loss of insulin producing cells to numbers below a threshold that is critically required to maintain physiologic glucoregulation. Prior to this threshold, however, escalating inflammation around (peri-insulitis) and in the islets of Langerhans (insulitis) first renders the insulin-producing beta cells insensitive to glucose and incapable of appropriate insulin production mainly due to the actions of cytokines like IFN, TNF and IL-1 (2; 3).

Upon clinical confirmation, a large number of type 1 diabetic patients still exhibit evidence of residual beta cell mass that, for a limited time is functionally responsive to glucose and produces insulin (the so-called "honeymoon period"; (4)). In fact, patients with a residual beta cell mass manifest better glycemic control, and improved prognosis for diabetic complications including retinopathy and nephropathy. These observations have compelled investigation into agents that can be used at the time of clinical diagnosis in order to preserve residual beta cell mass primarily by intervening with the ongoing autoimmunity. The use of pharmacologic systemic immunosuppressive drugs met with initial success in controlling autoimmunity, however upon withdrawal, the autoimmunity recurred indicating that systemic agents would need to be administered long-term with their associated adverse effects (5; 6). More recently, clinical reversal of hyperglycemia has been achieved by anti-CD3 antibody administration, although some questions linger regarding mechanism of action in the transient immunodepletion and associated cytokine-related side effects (7; 8). Finally, despite the initial observations in adults, administration of a peptide derived from HSP60 into new-onset diabetic children failed to exhibit any benefit compared to controls (9; 10). A need therefore remains for a diabetes-suppressive immunotherapeutic agent that does not engender non-specific systemic immunosuppression.

It is generally accepted that the initial wave of infiltrating immune cells in type 1 diabetes immunopathogenesis consists mainly of antigen presenting cells homing into the islets in response to an as-yet unidentified microenvironmental anomaly (11). While not completely resolved mechanistically and temporally, this anomaly, in a chronic process, compels migratory antigen presenting cells, and dendritic cells as most prominent, to acquire beta cell-resident antigens derived from apoptotic and/or necrotic beta cells. The migratory dendritic cells then undergo an intrinsic “maturation” program which renders them capable of activating T-cells (including autoreactive, beta cell-specific T-cells) as they accumulate inside the draining pancreatic lymph nodes (12-14).

Dendritic cells, however, also have the capacity to activate and maintain immunoregulatory, “suppressive” cell networks. Apparently, they are regulatory when in a state of functional “immaturity” (15-17). Functional immaturity can be conferred to dendritic cells partly by downregulating costimulatory pathways using systemic as well as molecule-specific approaches (18). Numerous studies have confirmed that exogenous administration of functionally-immature dendritic cells can facilitate allograft survival, and can also prevent autoimmune disease as well as its recurrence (18). We have shown that administration of dendritic cells from NOD mice with low-level expression of CD40, CD80 and CD86 - induced by ex vivo treatment with antisense oligonucleotides targeting the 5’ ends of the respective primary
transcripts - into syngeneic recipients can considerably delay and prevent the onset of disease (19; 20). This approach is now in a phase 1 clinical trial where autologous dendritic cells generated in vitro from leukapheresis products are being administered to established type 1 adult patients to determine safety (M.T. and N.G., FDA IND # BB-12858). Despite the promise of this study, we have encountered cumbersome logistical requirements to generate these dendritic cell embodiments. We are concurrently pursuing an alternative method to stabilise dendritic cell immaturity directly in vivo.

Many studies confirm that microparticle carriers can direct dendritic cells to the administration site and once phagocytosed, the contents can shape the dendritic cell functional phenotype (21; 22). Yoshida showed that biodegradable poly-(lactic-co-glycolic acid; PLGA) microspheres actually induce dendritic cell maturation by upregulating the CD40, CD80 and CD86 costimulatory molecules (22). Our studies required a nucleic acid delivery system that would be phagocytized by dendritic cells without upregulating these costimulatory molecules. We therefore chose to incorporate antisense oligonucleotides directed against the CD40, CD80 and CD86 primary transcripts were synthesized by the DNA synthesis facility at University of Pittsburgh (Pittsburgh, PA). The AS-oligonucleotides sequences are: seq ID 1:CD 40-AS: 5’C*A*C* A*G*C* C*G*A* G*G*C* A*A*A G*A*C* A*C*C* A*T*G* C*A*G* G*G*C* A-3’; seq ID 2: CD80-AS: 5’-G*G*G* A*A*A G*C*C* A*G*G* A*A*T* C*T*A* G*A*G* C*C*A* A*T*G* G*A-3’; seq ID 3: CD86-AS: 5’T*G*G* G*T*G* C*T*T* C*C*G* T*A*A* G*T*T* C*T*G* G*A*A* C*A*C* G*T*C-3’. Scrambled antisense oligonucleotides were also formulated into microspheres and used as nonsense controls in several experiments.

An aqueous solution of the oligonucleotide mixture was prepared by combining aliquots of three oligonucleotide solutions to form a 10 mg/ml solution. Ten mg/ml of poly-L-lysine-HBr in diH₂O (poly-L-lysine-HBr with an average molecular weight of 50,000 daltons by Bachem, King of Prussia, Pa.) was prepared. Poly-L-lysine-HBr was added to the oligonucleotide solution at a volumetric ratio of 1:1. The mixture was vortexed gently. A 25% polymer solution was prepared containing 12.5% PVP (polyvinyl pyrrolidone, with an average molecular weight of 40,000 Daltons, Spectrum Chemicals, Gardena, Calif.) and 12.5% PEG (polyethylene glycol, with an average molecular weight of 3,350 Daltons, Spectrum Chemicals, Gardena, Calif.) in 0.1M Sodium Acetate (Spectrum, Gardena, Calif.) at pH=5.5. The polymer solution was added in a
2:1 volumetric ratio as follows: 750 l of AS-oligonucleotides, 750 l of poly-L-lysine-HBr, 3.0 ml of PEG/PVP, to a final total volume of 4.5 ml.

The 4.5 ml preparation was incubated for 30 minutes at 70 °C and then cooled to 23 °C. The solution became turbid upon cooling and a precipitate was formed. The suspension was then centrifuged, and the excess PEG/PVP was aspirated. The resulting pellet was washed by resuspending the pellet in deionized water, followed by centrifugation and removal of the supernatant. The washing process was repeated three times. The aqueous suspension was frozen and lyophilized to form a dry powder of microspheres comprising oligonucleotide and poly-L-lysine. Particle size was determined using dynamic light scattering (Horiba LB-550 Nanoparticle Size Analyzer, Irvine, CA). Microsphere morphology was examined by scanning electron microscopy (Hitachi S-4800, Pleasanton, CA).

The weight percent load of the antisense oligonucleotide components in the microsphere was determined using gradient reverse phase HPLC with UV detection at 260nm (Waters Corporation, Milford, MA). The microspheres were deformulated using competitive displacement of the DNA oligonucleotides from the poly-L-lysine (PLL) using an excess of poly-L-aspartic acid sodium salt (PAA; Sigma Co., MW 5000-15000) in Tris EDTA buffer (pH 7.8) at 55 °C for 24 hours. The reverse phase HPLC was performed on a Waters XTerra MS C18 column (4.6X50mm). Mobile phase A was 8.6 mM TEA, 100 mM HFIP pH 8.2. Mobile phase B was Methanol. The oligonucleotides were eluted with a 30 minute gradient of 15% B to 18% B at a flow rate of 0.5mL/min. The column temperature was maintained at 60°C.

Approximately 1.1 mg of microspheres was suspended into 1.1mL of 1X phosphate buffered saline (pH 7.4) to measure in vitro release. The microspheres were centrifuged at several time points, the release media was aspirated and measured at UV 260 nm. Fresh release media was added to the microspheres until the next time point. The release studies were conducted at 22 °C and at 37 °C.

**Experimental Animals.** Female NOD/LtJ, NOD-scid, C57BL/6 and Balb/c mice were purchased from the Jackson Laboratories (Bar Harbor, ME) and used between the ages of 5-22 weeks. Animals were maintained in a specific pathogen-free environment in the Animal Facility of the Rangos Research Center and used in full compliance with experimentation protocols approved by the Animal Research Care Committee of the Children’s Hospital of Pittsburgh.

**Reagents, biochemicals and cell culture.** All biochemical and cell culture reagents were purchased from InVitrogen (Carlsbad, CA). Antibodies were purchased from BD Biosciences (San Diego, CA) either as directly conjugated fluorescent embodiments or as affinity-purified preparations in concert with fluorescently-labeled isotype-matched secondary products. The specific clones used were: CD4 clone: RM4-5; CD25 clone: 7D4. To ascertain the prevalence of Foxp3+ cells, we used the kit commercially available from eBioscience (San Diego, CA) which includes the FJK-16S Foxp3 clone. Spleen or lymph node-derived cells were enriched into T-cells using column methodology (R&D systems, Indianapolis, IN). The NIT-1 insulinoma cell line (ATCC CRL-2055) was maintained in Ham’s F-12K media with 2mM L-glutamine and 10% heat-inactivated fetal bovine serum until 70% confluence. The cells were then gently removed by collagenase digestion and made into lysates by repeated freeze-thaw cycles. The lysate was dispensed into aliquots in sterile PBS.

**AS-MSP administration.** Microspheres (MSP) formulated with the mixture of the CD40, CD80 and CD86 antisense oligonucleotides (AS-MSP) or with scrambled control sequences (SCR-MSP),
were dispensed into aliquots of 50 microgram oligonucleotide formulations in sterile PBS. One hundred microliters of the AS-MSP, SCR-MSP or PBS were injected subcutaneously, at a site anatomically-proximal to the pancreatic lymph nodes, into 5-8 week old NOD female mice in the initial prevention study. To determine their efficacy in new-onset diabetic NOD mice, we first treated diabetic mice (determined by two consecutive blood glucose measurements of >300 mg/dL) once daily with 2 units of a 1:1 Humulin R: Humulin N mix in PBS until nonfasting blood glucose stabilised to below 300 mg/dL. Insulin treatment was immediately stopped and the microsphere formulations injected subcutaneously, at a site anatomically-proximal to the pancreatic lymph nodes, three times a week until the mice were euthanised for further study.

Adoptive transfer of immune cells into NOD-scid recipients. To determine whether the microsphere administration induced regulatory immune cell populations, we isolated spleen from diabetes-free NOD mice administered the AS-MSP and made single cells. Parallel single cell preparations were enriched into T-cells. Splenocytes and enriched T-cells were co-transferred in equal numbers (1 x 10^7) into 7-10 week-old female NOD-scid recipients by intravenous injection. Diabetes was monitored on consecutive days, twice weekly.

FACS analysis. FACS analyses were performed on spleen or lymph node cells of successfully-treated NOD mice periodically. These were mice that were treated at < 10 weeks of age and remained diabetes-free or new-onset diabetic mice that were "reversed". Specifically, cell surface phenotype of the T-cells was assessed by FACS analysis in a FACS Vantage SE instrument using FACSDiva and CellQuest modules (BD Biosciences, San Jose, CA). In addition to the antibodies described above, relevant isotype-specific, fluorescently-conjugated antibodies were used throughout as controls for non-specific cell surface binding. Cells were incubated with mixtures of specific antibodies, and in parallel, with the isotype controls at titers between 1:100-1:500 as per the manufacturer’s suggestions. They were also labeled with either propidium iodide, 7-AAD and/or the annexin V-staining reagent (InVitrogen-Molecular Probes Inc.), and then used directly for FACS analysis. Percent positive cells or mean fluorescence intensity were measured for cells gated on forward and side scatter properties representing T-lymphocytes. Dead cells as well as cell clumps were excluded from the analyses, which were performed using the CellQuest software package.

T-cell proliferation assays in culture. To ascertain proliferation of T-cells from AS-MSP-treated NOD mice to alloantigens or nominal antigens, spleens were isolated from randomly-selected mice and enriched into T-cells. These were then co-cultured with equal numbers of irradiated splenocytes (1 x 10^5) from allogeneic mice or syngeneic mice in the presence/absence of 1 microgram intact ovalbumin. Proliferation was measured five days later using the CyQuant fluorometric reagent (InVitrogen-Molecular Probes) as directed by the manufacturer. The co-culture supernatants were retained to measure cytokine levels by Luminex-based fluorescence methods (Beadlyte, Upstate Biotechnology Inc.). To measure proliferation in response to the NIT-1 cell line-derived lysate, 1 x 10^5 splenocytes from treated NOD mice were co-cultured with an equal number of syngeneic and age-matched irradiated splenocytes with or without the addition of 5 micrograms of NIT-1 cell lysate. Following five days, the supernatant was removed for cytokine analysis and proliferation was measured.

Histology. The degree of insulitis in the pancreata of randomly-selected successfully-treated NOD mice was ascertained in serial
sections of formalin-fixed tissue by hematoxylin-eosin treatment. Additional sections were probed for insulin content using a commercially-available method (Vector BioLabs) with an insulin antibody (DakoCytomation, Carpinteria, CA).

**In vivo live-animal imaging.** NOD female mice (8 weeks of age) were anesthetized with isoflurane delivered by the XGI-8 Gas Anesthesia System (Xenogen). Initial isoflurane concentration was set to 2.5% and was reduced to 1.5% once the animal was anesthetized. Mice were imaged before injection on the IVIS Lumina (Xenogen) system using a dsRed filter set. Fluorescent exposure times of 0.8 sec were utilized for *in vivo* imaging and 0.1 sec for *ex vivo* imaging. Once imaged for background fluorescence, mice received a 300 µl injection by intraperitoneal injection that contained either a mixture of 150 µl of fluorescent microspheres (FluoSpheres™ 580nm/605nm, Molecular Probes-InVitrogen) and 100 µl of PBS (control), or 100 µl of fluorescent microspheres and 100 µl of 0.5 µg/µl antisense oligonucleotide mixture (CD40, CD80 and CD86), in a total volume of 300 µl. Spleens where excised at 1, 2, 3, and 6 days post injection. Single splenocytes were treated with Mouse BD Fc block (BD Pharmingen) for 5 minutes to reduce non-specific antibody binding. Cells were then treated with anti-mouse CD11c APC and CD40 PE, CD80 PE, or CD86 PE for 30 minutes (BD Pharmingen). After which the cells were washed and fixed in a 2% paraformaldehyde solution. Cells were then gated by FACS into CD11c and fluorescent microsphere double-positive cells and within this gate, CD40, CD80, and CD86 levels were further ascertained. Control isotypes were used throughout this experiment.

**Statistical analysis.** Student’s t-test, ANOVA and Kaplan-Meier log-rank analysis where described were facilitated using the Prism version 4 software by GraphPad (San Diego, CA).

**RESULTS**

**Characterization of antisense oligonucleotide-formulated PROMAXX microspheres (AS-MSP).** Scanning Electron Micrographs of the PROMAXX microspheres exhibited a relatively smooth surface (Figure 1A). The particle size of the microspheres determined by light scattering was 0.5-4 µm in size with an average particle size of approximately 2.5 µm. Thus, the calculated surface area of a single microsphere is approximately 19.6 µm². The loading of oligonucleotides determined by reverse phase HPLC in the microspheres was approximately 70% weight by weight. Based on these
measurements, the calculated number of copies of antisense oligonucleotide per microsphere was approximately $1.05 \times 10^8$. The in vitro release kinetics of the antisense oligonucleotides from the microspheres is shown in Figure 1B at 22 and 37 °C. The data show that after a small initial burst effect, the cumulative percent release is proportional to the square root of time. However after 120 hours, less than 1.1% of the incorporated antisense oligonucleotides have been released at 37 °C and less than 0.8% release was observed at 22 °C. This suggests that despite the 70% weight percent loading of oligonucleotide in the microspheres, most of the drug release occurs only after the microsphere has been uptaken by cells in vivo.

**Administration of diabetes-suppressive antisense oligonucleotide-formulated PROMAXX microspheres into pre-diabetic NOD female mice delays/prevents diabetes and reverses it in new-onset diabetic animals.** Our previous studies demonstrated that NOD-derived dendritic cells (DC) treated ex vivo with a mixture of phosphorothioated antisense oligonucleotides targeting the 5' end of the CD40, CD80 and CD86 primary transcripts, prevented diabetes in syngeneic recipients (19; 20). To determine if the microsphere-formulated antisense mixture was as efficacious, we administered AS-MSP targeting the 5' end of the CD40, CD80 and CD86 primary transcripts into NOD female mice between the ages of 5-8 weeks old. As controls, we concurrently treated parallel groups with PROMAXX formulation containing SCR-MSP and PBS vehicle. One single injection of AS-MSP, at a site anatomically-proximal to the pancreatic lymph nodes, significantly delayed onset of diabetes (Figure 1C), and eight consecutive injections (as illustrated in Figure 1D) were very efficacious in preventing the disease altogether. All NOD mice treated with control formulations and untreated NOD mice developed diabetes by 22 weeks of age. We are now determining if fewer consecutive injections can be as efficacious.

We then proceeded to determine if the AS-MSP could reverse new-onset hyperglycemia, which could suggest reversal of autoimmunity and mechanisms promoting preservation of residual beta cell mass in NOD mice. NOD mice between the ages of 12-16 weeks of age developed diabetes confirmed by two consecutive blood glucose readings of > 300 mg/dL. These mice were treated with daily insulin injections intraperitoneally until glycemia was stabilized to under 300 mg/dL. Decreased blood glucose was generally observed over 10-18 days period of insulin administration. The insulin was then immediately discontinued and either AS-MSP, SCR-MSP or PBS were injected subcutaneously, at a site anatomically-proximal to the pancreatic lymph nodes, twice weekly for no more than 25 days following the first microsphere administration (refer to diagram in Figure 2A). Figures 2B and 2C demonstrate that AS-MSP administration can reverse new onset hyperglycemia which is stably-maintained even after cessation of the microsphere treatment. This outcome is reproducible and in Figure 2D we show the outcome from three additional study groups. An additional 7/15 mice exhibited reversal of hyperglycemia and stable maintenance after cessation of the AS-MSP administration.

To ascertain the degree to which pancreatic inflammation was affected in NOD recipients of the AS-MSP that exhibited long-term protection from diabetes (treated with AS-MSP at <8 weeks of age; cohort shown in Figure 1D), we isolated pancreata from three randomly-selected AS-MSP recipients, SCR-MSP controls and diabetic NOD mice. While SCR-MSP-treated mice and diabetic controls exhibited significant insulitis and indistinguishable islet mass respectively, we observed normal islet architecture with an
absence of insulitis in AS-MSP recipients (Figure 3).

**AS-MSP treatment of NOD female mice augments the prevalence of Foxp3⁺ CD25⁺ putative Treg in vivo.** Our previous data suggested that the ex vivo antisense-treated DC were suppressive at least in part by augmenting the prevalence of CD4⁺ CD25⁺ putative T regulatory (Treg) cells (19; 20). We have now specifically addressed the question of whether AS-MSP directly augment Treg cells, by enumerating the percent of Foxp3⁺ CD25⁺ T-cells inside a CD4⁺ gate in the spleen and lymph nodes of pre-diabetic NOD females. Indeed, AS-MSP alone, and not the control microspheres or PBS, augmented the prevalence of Foxp3⁺ CD25⁺ T-cells (Figure 4).

Given that the AS-MSP treatment yielded augmented numbers of CD4⁺ CD25⁺ Foxp3⁺ putative T cells, it was logical to posit that a splenocyte population from AS-MSP-treated mice should be able to confer some degree of suppression to diabetes inducement in immunodeficient mice administered splenocytes from diabetic NOD mice. Towards this objective, a 1:1 mix of splenocytes from AS-MSP-treated diabetes-free NOD mice and new-onset diabetic NOD mice was injected into female NOD-scid mice between 6-10 weeks of age. As controls, a 1:1 mix of splenocytes from non-diabetic 10 week-old NOD mice were treated with either SCR-MSP (8 consecutive s.c. injections spaced every three days apart) and splenocytes from diabetic mice were injected into 6-10 week-old NOD-scid females. In addition another control group of NOD-scid mice was injected with splenocytes from new-onset diabetic NOD mice. Each cell population consisted of 1 x 10⁷ splenocytes freshly-isolated. Blood glucose was monitored twice weekly and two consecutive readings of non-fasting glucose >300 mg/dL was considered as the diabetic threshold. Figure 5 demonstrates that adoptive transfer of diabetes in NOD-scid recipients was almost completely abrogated in the presence of splenocytes derived from AS-MSP recipients that were diabetes-free.

**In vivo-injected AS-MSP accumulate within the pancreatic lymph nodes and spleen and confer decreased co-stimulatory molecule surface expression on splenic DC in vivo.** To determine the route of migration of the AS-MSP, which could offer insight into the mechanism of immunoregulation and diabetes suppression, we used in vivo imaging technology to observe the temporal accumulation of a 1:1 mix of commercially-available fluorescent microspheres and the AS-MSP. The sizes of the commercially purchased fluorescent microspheres (FluoSpheres) were considerably smaller than the particle size of the AS-MSP. The AS-MSP were 2.5 microns on average and the FluoSpheres were 0.2 microns on average. Thus the FluoSpheres should not interfere with the uptake of the AS-MSP by dendritic cells. In Figure 6 we show that as early as 3 hours following intraperitoneal injection, the fluorescent microspheres accumulated at anatomical sites where the pancreas and the spleen reside (Figure 6A). The intensity of the fluorescence did not change over a 72 hour monitoring period (data not shown). To confirm the accumulation of the microspheres within the pancreas and spleen, we excised these two organs from the mice that were being monitored live and in Figure 6B we confirm that, indeed, the fluorescent microspheres accumulated as early as 3 hours post-injection at distinct foci in pancreas and spleen. Although accumulation of fluorescent microspheres was observed in these two organs regardless of whether AS-MSP were included in the mix or not, the actual intensity of the fluorescence was different in organs excised at the times indicated in Figures 6C and 6D. The fluorescence was evident in the
spleen and pancreata of all mice at all time points studied (from 3 hours to 6 days following injection; Figure 6 and data not shown).

As an additional confirmation that oligonucleotide-formulated microspheres accumulate inside the pancreas and spleen, we injected PROMAXX-formulated Cy3-labeled siRNA to CD86 identically as described above. We also compared the pancreatic accumulation of this Cy3-labeled formulation following intraperitoneal injection, subcutaneous injection at a site distal to the anatomic location of the pancreatic lymph nodes (at the scruff of the mouse) and subcutaneous injection at the site used in the prevention and reversal studies documented herein (flank of the mouse). Figure 6E confirms the pancreatic accumulation of PROMAXX-formulated Cy3-labelled oligonucleotide at 3 hours post-injection, but only when the subcutaneous injection was performed anatomically-proximal to the pancreatic lymph nodes.

To confirm that AS-MSP administration conferred a decrease in CD40, CD80 and CD86 in DC in vivo, we injected NOD mice intraperitoneally, with a mixture of the FluoSpheres with PBS as control or with AS-MSP as described in the methods. At the times indicated at the top of each graph in Figure 6F, we excised the spleen and measured CD40, CD80 and CD86 levels in CD11c+ fluorescence+ double-positive single cells. We observed a decreased level of all three co-stimulatory molecules on CD11c+ cells that had concentrated the mixture of fluorescent microspheres and AS-MSP as early as one day following injection with maintenance of these levels compared to CD11c+ cells from control mix-treated NOD mice over a six day monitoring period. The only exception was seen at day 3 for CD40.

**AS-MSP treatment of NOD prediabetic female mice yields T-cells hyporesponsive to NIT-1 cell lysate in vitro without inducing non-specific immunosuppression.**

A major concern for eventual translation of diabetes-suppressive therapies into human trials is the antigen specificity and therefore the cell specificity of the approach and if the treatment confers global and non-specific suppression. To address these issues, we euthanised randomly-selected diabetes-free mice from the cohorts shown in Figure 1D and we then proceeded to ascertain the proliferation of splenic and lymph node T-cells to alloantigens, nominal antigens using intact ovalbumin and also using syngeneic beta cell-derived antigen in the form of cell lysate from the NOD derived insulinoma cell line NIT-1 (24; 25). While insulin and GAD are viable candidate autoantigens with mechanistic and teleologic involvement (26), the nature of the initiating autoantigen remains unclear. Nevertheless, it is reasonable to consider that it should be beta-cell resident. Therefore, we used the NIT-1 cell line which derives from an NOD insulinoma as a source of beta cell antigen in cocultures of T-cells from diabetes-free NOD mice treated with the AS-MSP to determine the possibility of antigen-specific hyporesponsiveness. Supporting Information (SI) Figure 7 shows that T-cell proliferation to nominal and alloantigen is maintained whereas there is T-cell hypoproliferation in cocultures with NIT-1 cell lysate. Furthermore, ascertaining the cytokine profile in the co-culture supernatants, we observed a significant decrease in TNF production by T-cells from AS-MSP-treated, diabetes-free NOD mice even in the presence of NIT-1 lysate (SI Figure 7F; from those diabetes-free NOD mice in Figure 1D). Although IFN production was slightly decreased in the co-cultures of T-cells from the AS-MSP-treated mice, it was not statistically-distinguishable from the co-cultures with T-cells from PBS-treated mice in the presence of NIT-1 lysate. The assay, finally, could not detect the
Diabetes-suppressive microspheres

**DISCUSSION**

Formulation of bioactive agents into microparticles offers a versatile means of delivering these molecules in vivo especially for the purpose of modulating the immune system (21; 27). An important component of the modulatory properties of microspheres is the polymer backbone which often stimulates potent antigen-presenting cell activation which is beneficial for tumor immunotherapy or antipathogen interventions (28; 29). For the purposes of immunosuppression however, the polymer and the component chemistries should be such that at the very minimum they should be neutral on antigen-presenting cell state. PROMAXX nucleic acid microspheres offers this versatility (23) as a result of the minimal quantity of formulation excipients. In this regard, we now show its utility as a key component of a diabetes-suppressive vaccine.

The most noteworthy finding in these studies is the capacity of the AS-MSP to reverse new-onset hyperglycemia which we believe is underlined by preservation of residual beta cell mass. Nevertheless, we cannot yet formally distinguish this from a potential regenerative process of beta cells (division of existing beta cells or differentiation of progenitor/stem cells from ductal epithelium; (30-32)). There is, however, considerable support from previous studies for a sufficiency in beta cell mass that is functionally-responsive to glucose at the time of diagnosis of type 1 diabetes (32-36). This mass, if permitted to recover from autoimmune attack by modulating the aggressive and beta cell-specific immune cells, may provide the patient with normoglycemic metabolic control.

Although our data herein are not the first to demonstrate small molecule-based diabetes prevention in the NOD mouse, they are the first to show a well-defined microparticle system that can reverse hyperglycemia in new onset disease whose mechanism of action is decipherable. In preliminary studies, we have observed that when the formulation was injected into NOD-scid immunodeficient mice reconstituted with splenocytes from NOD mice of various diabetes stages (young, 12-15 week-old where autoimmunity is already established and where beta cell function is impaired, and from new-onset diabetics), the prevalence of CD4⁺ CD25⁺ putative T regulatory cells increased. We have now confirmed herein in a more direct experiment, that CD4⁺ CD25⁺ Foxp3⁺ T-cells numbers increase in female NOD mice administered AS-MSP. These findings may explain the capacity of T-cells from AS-MSP-treated NOD mice free of diabetes to prevent the adoptive co-transfer of the disease to NOD-scid recipients. More importantly, T-cells from diabetes-free AS-MSP exhibited poor proliferation to NIT-1 lysate in vitro while proliferating vigorously in cocultures with allogeneic irradiated splenocytes or when pulsed with ovalbumin.

Many lines of evidence conclude that injected microsphere formulations are rapidly taken up by resident and/or migratory antigen presenting cells, especially DC and accumulate inside lymphoid organs anatomically-proximal to the site of injection. Our studies in the past have also confirmed this uptake/trafficking (K.N., J.H., N.G., unpublished observations). Herein we have provided some of these data which confirm that subcutaneously-injected microspheres accumulateas early as three hours after injection within the pancreas, very possibly in the lymph nodes, and eventually in the spleen. Although we do not explicitly demonstrate it, we are very confident that the most likely method of microsphere accumulation inside the pancreas is via dendritic cells. Of wide interest is the mechanism by which antigen and therefore cell/tissue specificity is acquired by the
microsphere-loaded dendritic cells. A series of elegant studies (12-14; 17) point to a process where migratory DC potentially acquire the microspheres that are injected physically-proximal to a site of ongoing inflammation and, guided by pro-inflammatory signals deriving from the diabetic pancreas, acquire pancreatic beta cell antigens in the form of apoptotic cells at a site of inflammation. Then, these DC will exit the inflamed tissue and accumulate within the regional lymphoid organs where they can engage not only effector T cells, but Treg cells as well (12-14; 17; 33). Indeed, it has been shown that DC that acquire apoptotic cells enter into a state of functional immaturity which may result in tolerance to the acquired antigens (17; 34). We hypothesize that a similar, if not identical, process is occurring immediately after AS-MSP administration in NOD mice. The inflammation inside the pancreas with associated beta cell apoptosis will drive AS-MSP-loaded dendritic cells to acquire beta cell antigen and immediately thereafter, their accumulation inside the pancreatic lymph nodes will facilitate their interaction with Treg cells which may - in themselves, or in concert with AS-MSP-stabilised dendritic cell or other endogenous dendritic cell subsets - induce beta cell-specific immune hyporesponsiveness or functional tolerance to beta cell-restricted antigens (35-37). Indeed, we show that microsphere-loaded dendritic cells in the spleen express decreased levels of CD40, CD80 and CD86 at their surface and we anticipate that this is true for dendritic cells in the pancreatic lymph nodes. Although we do not currently have an explanation for the increase in CD86 levels in fluorescent dendritic cells from the spleen of mice treated with the AS-MSP mixture at day 6 after administration, this could reflect the eventual degradation of the antisense nucleic acid in the dendritic cells by day 6, the disappearance of the migratory dendritic cells and acquisition of the fluorescent particles by endogenous, secondary dendritic cells in a cross-priming mechanism or both.

What has become apparent in these preliminary accumulation studies is the differential accumulation of microspheres inside the pancreas following subcutaneous injection depending on the proximity of the injection site to the pancreas. When administered subcutaneously at a site that flanks the site of the pancreatic lymph nodes, the microspheres accumulate within three hours. In contrast, there is no detectable accumulation when the microspheres are administered subcutaneously at a site that does not drain to the pancreatic lymphatics. This observation is relevant for two reasons. First, it offers insight into which administration route may be more clinically-useful. Second, it suggests that immunoregulatory interventions, at least those which involve dendritic cells as intermediates, are mechanistically-active only when the pancreatic lymph nodes are involved (i.e. the nexus of autoimmune cells and regulatory cells that exhibit antigen-specificity). We are, consequently, very interested in identifying the precise mechanism involved in co-stimulatory protein surface density changes at the dendritic cells in spleen and in pancreatic lymph nodes in response to the AS-MSP treatment. The scarcity of dendritic cells from the pancreatic lymph nodes at the times shown in Figure 6 did not permit us to pursue an effective enrichment of these cells, but it is one of our objectives in future studies where the precise mechanisms and temporal sequence of cell migration and interaction with other cells in the pancreatic lymph nodes and/or at the islets of Langerhans remain to be established.

Many investigators support immunotherapy approaches for autoimmunity where putative autoantigen supply provides the antigen, and hence the tissue, specificity (38-41). It is worth noting, however, that
suppression of autoimmune disease in animal models need not require antigen supply (37). Mechanistically, such interventions may involve bystander tolerance, linked suppression or similar phenomena (37; 42; 43). Although we did not supply autoantigen to the AS-MSP regimen, we did inject diabetic NOD mice with insulin to normalize the glycemia. In one possible mechanism the exogenous insulin supply (as a well-characterised putative autoantigen), prior to AS-MSP administration may be acting similar to, or in an identical manner as earlier insulin-based tolerance strategies (1; 38-41). However, we think a more likely mechanism is that the AS-MSP stabilized subsets of endogenous dendritic cells towards diabetes-suppressive states by downregulating cell surface CD40, CD80 and CD86. We are currently actively investigating the possible mechanism experimentally. It must be stressed, concurrently, that insulin administration alone cannot account for the AS-MSP effects, in its physiologic glucoregulatory capacity. No mouse in groups treated with insulin alone was capable of maintaining normoglycemia for more than one week following withdrawal of the insulin (Figure 5). This argues against the possibility that in the AS-MSP-treated animals, new-onset diabetes reversal was due to insulin-induced beta cell rest phenomena (44; 45). Taken together, these findings may be readily translatable clinically with an immediate aim of preserving residual beta cell mass in newly-onset or preclinical human autoimmune diabetes.

ACKNOWLEDGMENTS
This work was supported in part by the NIH (DK063499 to MT and NG), by the JDRF (17-2007-1066 to NG) and by a preclinical discovery research contract to NG from Epic Therapeutics, a wholly-owned subsidiary of Baxter Health Care Corporation. William Fowle at the Electronic Materials Research Institute at Northeastern University, Boston, MA, conducted the scanning electron microscopy studies.
REFERENCES


29. Davis SS: The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine 24 Suppl 2:S2-7-10, 2006
CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. *Proc Natl Acad Sci U S A* 103:2758-2763, 2006


FIGURE LEGENDS

FIGURE 1
A. Scanning electron micrograph of the antisense oligonucleotide microspheres (AS-MSP). The micrograph exhibits an essentially smooth surface with particle diameters in the 1 to 4 micron size range. Size bar is shown at bottom of the micrograph.

B. The cumulative percent release of antisense oligonucleotides from the microspheres. The cumulative percent release was observed to be directly proportional to the square root of time. At 22 °C, approximately 0.8% of the oligonucleotide was released, and at 37 °C, about 1.1% of the incorporated oligonucleotide was released. The release kinetics appears to conform to matrix diffusion release mechanism.

C. AS-MSP administration into NOD mice at 5-8 weeks of age delays diabetes onset. Two groups of NOD female mice (5-8 weeks old) were given a single subcutaneous injection of microsphere-formulated antisense-oligonucleotides, at a site anatomically-proximal to the pancreatic lymph nodes. The formulation was injected in the amount of what was considered to contain 50 mg of a 1:1:1 mixture of each antisense oligonucleotide (anti-CD40, anti-CD80 and anti-CD86) or scrambled sequences (SCR-MSP) or PBS vehicle (control). Tail vein blood glucose was measured weekly. Diabetes was confirmed after two consecutive readings of >280-300 mg/dL. The graph shows cumulative survival of two independently-treated cohorts. P<0.0001, Kaplan-Meier analysis.

D. Frequent AS-MSP administration into NOD mice at 5-8 weeks of age prevents diabetes onset. NOD female mice (5-8 weeks old) were given eight consecutive single subcutaneous injections, at a site anatomically-proximal to the pancreatic lymph nodes, (once weekly) of microsphere-formulated antisense-oligonucleotides. The formulation was injected in the amount of what was considered to contain 50 g of a 1:1:1 mixture of each antisense oligonucleotide (anti-CD40, anti-CD80 and anti-CD86; AS-MSP) or scrambled sequences (SCR-MSP) or PBS vehicle (control). Tail vein blood glucose was measured twice weekly. Diabetes was confirmed after two consecutive readings of >280-300 mg/dL. P<0.0001, Kaplan-Meier analysis.

FIGURE 2. Multiple rounds of AS-MSP administration into new-onset diabetic NOD female mice with Improved blood glucose levels; stable fasting euglycemia even after AS-MSP withdrawal. Diabetes onset was confirmed by two consecutive blood readings of >300 mg/dL. Insulin was administered daily until blood glucose fell below 300 mg/dL. Insulin was immediately stopped and the AS-MSP administrations (at a site anatomically-proximal to the pancreatic lymph nodes) began as shown in the timeline (A). In some mice, AS-MSP administration was withdrawn as shown in (A). The data show the mean non-fasting blood glucose (B) and the mean fasting blood glucose (C) +/- SEM. The graphs (D) show reversal of new-onset diabetes in separate groups of diabetic mice following multiple AS-MSP administrations as described in methods.

staining of representative serial sections from diabetic, SCR-MSP diabetic and diabetes-free AS-MSP. Sections are representative of three randomly selected NOD mice in each group.

**FIGURE 4.** T-cells from AS-MSP-treated, diabetes-free NOD mice exhibit increased prevalence of Foxp3+ CD25+ putative Treg. T-cells were enriched from the spleen or the pooled lymph nodes of AS-MSP-treated diabetes-free mice selected at random from the AS-MSP diabetes-free cohort shown in FIGURE 1D. All mice treated with PBS or SCR-MSP developed diabetes as shown in the same FIGURE 1D. At the time of diabetes confirmation, T-cells were harvested from spleen and pooled lymph nodes. The cells were then stained intracellularly for Foxp3 and with CD25 and the % of double-positive cells in a lymphocyte population was determined by FACS analysis. An example of the gating is shown in (A). The scatter gram in (B) shows the % of double-positive cells in individual mice at the time of euthanasia in spleen and in (C) the % of putative Treg in pooled lymph node is shown. P<0.001 between AS-MSP-treated mice and the two controls in both graphs by Mann-Whitney U-test.

**FIGURE 5.** Co-transfer of splenocytes from AS-MSP-treated, diabetes-free NOD mice suppresses the adoptive transfer of diabetes into NOD-scid mice by splenocytes from diabetic NOD donors. Four out of 5 NOD-scid recipients of splenocytes from AS-MSP-treated NOD mice and diabetogenic splenocytes remained diabetes-free at 16 weeks after cell transfer whereas only 2/5 and 0/5 were diabetes-free following co-transfer of diabetogenic splenocytes and splenocytes from SCR-MSP and PBS-treated NOD mice, respectively. In the graph inset, Spl refers to splenocytes and p.t. refers to the time the mice were euthanised for further analysis post-transfer. Splenocytes from randomly-selected diabetes-free AS-MSP-treated mice from the treatment groups shown in FIGURES 1C and 1D (single or multiple AS-MSP injections) were co-transferred into female NOD-scid mice of 10 weeks of age along with an equal number of splenocytes (1 x 10^7) from new-onset diabetic NOD female mice (15-18 week old). Diabetes was monitored once weekly in tail vein blood. Levels of >280 mg/dL at two consecutive readings were deemed to indicate diabetes. There were five NOD-scid recipients per co-transfer groups as shown below in the graph. P=0.0003, between control and AS-MSP splenocyte recipients, Kaplan-Meier analysis.

**FIGURE 6**

**In vivo accumulation of AS-MSP.** NOD mice received a subcutaneous injection containing a 1:1 mix of 0.2 µm diameter fluorescent microspheres and sterile PBS or fluorescent microspheres with 50 µg of AS-MSP.

A. *In vivo* imaging of mice was performed 3 hours post injection. The injection site is clearly visible as well as regions with microsphere accumulation (anatomically located in the area of the pancreas and the spleen).

B. The spleen and pancreas was removed from animals at 3, 24, and 48 hours post injection and imaged. The excised spleens are at the top two panels of each quadrant (spleen from mice receiving the fluorescent microspheres+PBS on left and spleen from mice receiving the
fluorescent microspheres+AS-MSP on the right) and the pancreata are shown at the bottom panels.

C and D. The mean radiance per area was quantified for the excised spleen and pancreas and graphically shown below the imaging figures. The graphs represent organs from one mouse and the differences in the magnitudes of radiance are representative of organs from three separate mice.

E. Comparison of intraperitoneal versus subcutaneous administration of directly-labeled oligonucleotide microspheres on accumulation inside the pancreas. NOD mice were injected with a PROMAXX formulation of a Cy3-labeled siRNA targeting the CD86 gene via subcutaneous route at a site anatomically-distal and proximal to the pancreatic lymph nodes. Three hours after injection, the pancreata and spleens were harvested and imaged as described in Methods. CN refers to organs from mice administered PBS vehicle alone, IP refers to animals receiving microsphere-formulated Cy3-conjugated oligonucleotide by intraperitoneal route and SubQ refers to animals receiving microsphere-formulated Cy3-conjugated oligonucleotide by subcutaneous route. Subcutaneous delivery was made into the scruff of the animal (close to the neck; NECK) and into the flank anatomically-proximal to the pancreatic lymph nodes (FLANK).

F. AS-MSP administration does not increase co-stimulatory levels on spleen-derived DC in vivo. NOD mice were treated with a 1:1 mix of fluorescent microspheres and PBS (CN), or with fluorescent microspheres and 50 µg of the antisense oligonucleotide mixture (AS) by subcutaneous injection. Spleens were harvested and single cells were stained with CD40, CD80, CD86 and CD11c antibodies. The cells were analyzed by flow cytometry at Day 1, 2, 3, and 6 days post injection. Cell populations that stained positive for CD11c and fluorescent microspheres were then gated to measure the presence and levels of CD40, CD80, or CD86. The graphs show the median of the costimulatory molecule levels of spleen cells from individual mice (horizontal bar) as the percent of costimulatory molecule inside a CD11c+ fluorescent bead+ gate. p<0.05 by Mann-Whitney U-test between control and AS-MSP mix-treated mice for CD86 on Day 1; for CD40, CD80 and CD86 on Day 2; for CD40 on Day 3.
Diabetes-suppressive microspheres

**FIGURE 1A**

**FIGURE 1B**

**FIGURE 1C**

**Survival of NOD mice Tx w/ 1 MSP injection**

- ▲ control NOD (n=9)
- ■ AS-MSP (n=23)
- ○ SCR-MSP (n=12)

Remaining live mice euthanised for further characterisation of immune cells.

Injected s.c. at 5-8 weeks of age.
FIGURE 1D

Survival of NOD mice Tx w/ 8 MSP injections

- △ control NOD (n=8)
- □ AS-MSP (n=14)
- ● SCR-MSP (n=8)

6 mice euthanised for immune cell characterisation.

MSP s.c. injections from 5-13 weeks of age; once weekly (50 µg equivalents of AS-MSP or SCR-MSP). Injections stopped on week 13.

FIGURE 2

A. Diabetes confirmed
Start daily insulin
Time (days)
0
1-3
5-8
Stop insulin; Start MSP (twice weekly)
Stop MSP
30-34

B. Non-fasting blood glucose (mg/dL)

None of the control groups survived past 30 days.***

C. Fasting blood glucose (mg/dL)
Diabetes-suppressive microspheres

**Figure 2D**

Diabetic NOD

SCR-MSP NOD (hyperglycemic)

AS-MSP-treated diabetes-free NOD mice

**Figure 3**

H&E

Insulin staining

Diabetic NOD

SCR-MSP NOD (hyperglycemic)

AS-MSP-treated diabetes-free NOD mice
Diabetes-suppressive microspheres

**FIGURE 4**

A. Gating for FACS

B. Splenic T-cells

C. Pooled lymph node T-cells

**FIGURE 5**

**DIABETES INCIDENCE IN NOD-SCID RECIPIENTS**
- Spl from diabetic NOD mice: 0/5 at 16 weeks post transfer (p.t.)
- Spl from single AS-MSP inj. mice: 2/5 at 16 weeks p.t.
- Spl from multiple AS-MSP inj. mice: 4/5 at 16 weeks p.t.
Figure 6E
Diabetes-suppressive microspheres

**FIGURE 6F**

<table>
<thead>
<tr>
<th></th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
<th>Day 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD86</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>